Rafferty Asset Management LLC, an institutional investor, has decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 19.9% during the fourth quarter. The company sold 29,910 shares of Kymera Therapeutics, reducing its holdings to 120,189 shares. This represents a decrease of about 0.22% of Kymera Therapeutics' total shares. The value of Rafferty Asset Management LLC's holdings in Kymera Therapeutics is estimated to be $3,060,000. Other institutional investors, including Vanguard Group Inc., Rock Springs Capital Management LP, FMR LLC, and Norges Bank, have also made changes to their positions in Kymera Therapeutics. Vanguard Group Inc. increased its position by 4.9% during the third quarter, while Rock Springs Capital Management LP increased its position by 1.1%. FMR LLC increased its position by 3.9% during the third quarter, and Norges Bank acquired a new position in the fourth quarter. Massachusetts Financial Services Co. MA also grew its position by 23.0% during the third quarter. [9dcb8491]
Kymera Therapeutics is a biotechnology company that focuses on developing targeted protein degradation therapies for patients with previously untreatable diseases. The company's innovative approach has attracted the interest of institutional investors, who see the potential for significant growth in the field of protein degradation. Kymera Therapeutics aims to harness the body's natural protein degradation system to remove disease-causing proteins and restore normal cellular function. The company's pipeline includes multiple programs targeting a range of diseases, including cancer, immune-inflammatory disorders, and neurodegenerative diseases. Kymera Therapeutics' mission is to improve the lives of patients by developing breakthrough therapies that address the underlying causes of disease. [f09187be]